Ace Therapeutics, a preclinical contract research organization specializing in analgesic drug research, has announced a comprehensive suite of end-to-end solutions for pain therapeutic development. The company's integrated platform features diverse validated in vivo pain models for drug testing, covering nearly all mainstream pain classifications, and a complete range of preclinical research capabilities for pharmaceutical and biotechnology clients worldwide.
The new services address the complex demands of modern pain drug research by covering every stage from early target discovery and mechanism verification through pharmacological validation and safety assessment. According to the company, its core strength lies in an extensive portfolio of standardized and customized in vivo pain models, including migraine models established via trigeminal ganglion electrical stimulation and nitroglycerin induction, as well as neuropathic pain models such as spinal nerve ligation, chronic constriction injury, and diabetic neuropathic pain models.
To complement these in vivo systems, Ace Therapeutics has developed systematic preclinical pain assessment services that include mechanical, thermal, chemical, cold, and electrical stimulation pain assessments using methods like the Von Frey Filament Test, Hot Plate Test, and Formalin Test. The company also offers in vitro neuropathic pain model development services leveraging dorsal root ganglion cells, iPSC-derived sensory neurons, and various co-culture systems to explore pain-related cellular mechanisms, enhancing translational value.
Beyond model construction, Ace Therapeutics' services extend to target-based and modality-based drug discovery, supporting research on G-protein coupled receptors, cytokine networks, and ion channels. These services deliver professional solutions for small-molecule analgesics, biologics including antibodies, recombinant proteins, peptides, cell therapies, and gene therapy candidates. Mechanism-driven research covers peripheral inflammatory pathways, central regulatory pathways, neuronal signaling pathways, and neuro-immune interaction pathways.
The full-service pipeline also includes target validation, in vitro screening, in vivo pharmacology, pharmacokinetics analysis, safety pharmacology, preclinical formulation development, and biomarker discovery. Professional PK/PD modeling, toxicity assessment, and formulation optimization help clients reduce research risks, determine optimal dosages, and accelerate candidate selection. For special needs, Ace Therapeutics can design customized pain models and testing assays according to unique drug mechanisms.
This announcement is significant because chronic pain affects millions worldwide, and developing safer, more effective analgesics remains a critical unmet need. By offering a comprehensive, one-stop preclinical research platform, Ace Therapeutics aims to streamline the drug development process, potentially reducing time and costs for pharmaceutical companies. The ability to test candidates across multiple pain models simultaneously could improve translational success rates, ultimately benefiting patients suffering from conditions like migraine, neuropathic pain, and diabetic neuropathy. As the opioid crisis continues to underscore the need for non-addictive pain treatments, such specialized contract research services play a vital role in advancing novel analgesic candidates from bench to bedside.
